《盈警響號》中國新城市(01321.HK)料中期綜合虧損淨額擴大至約2.39億人幣
中國新城市(01321.HK)指,截至2022年6月30日止六個月,因新冠肺炎疫情及外部經濟壓力為整個行業帶來更嚴峻的挑戰,商業及酒店分部處於異常狀態,預期收益及毛利較截去年同期各自大幅減少分別約人2.9億元人民幣(下同)或53%,及約7,000萬元或58.9%,而綜合虧損淨額由上年同期6,770萬元擴大至2.39億元,主要由於集團於2022年期間錄得投資物業公允價值減少約9,560萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.